Immuno-Biological Laboratories CoTSE:4570 +0.84%59 Interest Coverage is 217.10 as of Mar. 2026, which is 68% above its 10-year median of 129.23. GuruFocus rates TSE:4570 with a GF Score™ of 59/100 and a GF Value™ of 円577.29 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 377 Biotechnology companies, Immuno-Biological Laboratories Co ranks better than 53.58% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Immuno-Biological Laboratories Co's
Operating Income
for the
six
months ended in Mar. 2026 was 円139 Mil. Immuno-Biological Laboratories Co's Interest Expense for the
six
months ended in Mar. 2026 was 円-1 Mil.
Immuno-Biological Laboratories Co's interest coverage for the quarter that ended in Mar. 2026 was 217.10.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Immuno-Biological Laboratories Co Ltd has enough cash to cover all of its debt. Its financial situation is stable.
The historical rank and industry rank for Immuno-Biological Laboratories Co's Interest Coverage or its related term are showing as below:
TSE:4570'
s Interest Coverage Range Over the Past 10 Years
Min: 53.27 Med: 129.23 Max: 211.02
Current: 211.02
TSE:4570's Interest Coverage is ranked better than 53.58% of 377
companies
in the Biotechnology industry
Industry Median: 106.07
vs TSE:4570: 211.02
Immuno-Biological Laboratories Co (TSE:4570) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Immuno-Biological Laboratories Co Interest Coverage Related Terms
Immuno-Biological Laboratories Co Interest Coverage Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Immuno-Biological Laboratories Co Interest Coverage Chart
TSE:4570 vs VRTX, REGN, ALNY: Interest Coverage Comparison
For the Biotechnology subindustry, Immuno-Biological Laboratories Co's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immuno-Biological Laboratories Co Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Immuno-Biological Laboratories Co's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Immuno-Biological Laboratories Co's Interest Coverage falls into.
Immuno-Biological Laboratories Co Interest Coverage Calculation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immuno-Biological Laboratories Co (TSE:4570) has a Interest Coverage of 217.10 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Immuno-Biological Laboratories Co and its competitors. This is 68% above median its historical median of 129.23. Over the past decade, Immuno-Biological Laboratories Co's Interest Coverage has ranged from 53.27 to 211.02. According to the industry distribution chart, Immuno-Biological Laboratories Co ranks #175 out of 377 companies in the Biotechnology industry, placing it in the top 46.4%.
Is Immuno-Biological Laboratories Co's Interest Coverage too high?
Immuno-Biological Laboratories Co's current Interest Coverage of 217.10 is 68% above median its 10-year median of 129.23. Over the past 10 years, this metric has ranged from a low of 53.27 to a high of 211.02. The Biotechnology industry median Interest Coverage is 106.07. Immuno-Biological Laboratories Co's value of 217.10 is 104.7% above this industry median. Based on the distribution chart, Immuno-Biological Laboratories Co ranks #175 out of 377 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Immuno-Biological Laboratories Co has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Immuno-Biological Laboratories Co's Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Immuno-Biological Laboratories Co ranks #175 out of 377 companies for Interest Coverage. This puts Immuno-Biological Laboratories Co in the upper half of its industry. The industry median Interest Coverage is 106.07. Immuno-Biological Laboratories Co's value of 217.10 is 104.7% above this benchmark. Historically, Immuno-Biological Laboratories Co's own Interest Coverage has ranged from 53.27 to 211.02 over the past decade. While the company's 10-year median is 129.23 vs. the industry median of 106.07, Immuno-Biological Laboratories Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 106.07, based on 377 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Immuno-Biological Laboratories Co's current Interest Coverage of 217.10 is 104.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Immuno-Biological Laboratories Co and its competitors. For the Biotechnology industry, the median Interest Coverage is 106.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Immuno-Biological Laboratories Co's current Interest Coverage is 217.10, which is 68% above median its own 10-year median of 129.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immuno-Biological Laboratories Co stock overvalued right now?
Based on GuruFocus' analysis, Immuno-Biological Laboratories Co (TSE:4570) is currently considered Significantly Overvalued. The stock's GF Value™ is 円577.29, compared to a current price of 円963.00 — trading 66.8% above its estimated fair value. The current Interest Coverage is 217.10, which is 68% above median its 10-year median of 129.23 and 104.7% above the Biotechnology industry median of 106.07. Immuno-Biological Laboratories Co's overall GF Score™ is 59/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Immuno-Biological Laboratories Co (TSE:4570), the current Interest Coverage is 217.10 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Immuno-Biological Laboratories Co (TSE:4570) Overvalued in 2026?
Based on GuruFocus' analysis, Immuno-Biological Laboratories Co stock appears to be overvalued.
The current stock price of 円963.00 is trading 66.8% above its estimated GF Value™ of 円577.29.
GuruFocus considers Immuno-Biological Laboratories Co to be Significantly Overvalued.
Key valuation signals for TSE:4570:
Interest Coverage: 217.10 (68% above median its 10-year median of 129.23)
GF Value™: 円577.29 vs. price of 円963.00 (66.8% above fair value)
Industry Position: 104.7% above the Biotechnology median (#175 of 377)
No single metric tells the full story. See the TSE:4570 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Immuno-Biological Laboratories Co Business Description
Immuno-Biological Laboratories Co Ltd focuses on research and development. It researches, develops, manufacture and supplies various immunological research reagents, and customized services. It is engaged in research and development of materials used in diagnostic products and valuable seeds and technology for protein production using transgenic silkworm cocoons, which make it possible to create valuable proteins as well as antibodies. It works on clinical reagents for cancer research. Its research scientists are producing inflammatory cytokines, growth factors & antibodies for use against these cancers.
59GF Score
Get the complete analysis for TSE:4570
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4570 has been successfully added to your 
